Methylated DNA as a possible screening marker for neoplastic disease in several body fluids

Expert Review of Molecular Diagnostics

Volumn 3, Issue 4, 2003, Pages 443-458

  Müller, Hannes M ^a   Widschwendter, Martin ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Body fluid; DNA methylation; Early detection; Free DNA; Neoplasia; Plasma; Screening marker; Serum

Indexed keywords

BODY FLUID; CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CPG ISLAND; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA METHYLATION; DNA MICROARRAY; EARLY DIAGNOSIS; HUMAN; PAPANICOLAOU TEST; REVIEW;

EID: 0038159962     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.4.443     Document Type: Review

References (142)

1. Etzioni R, Urban N, Ramsey S et al. Early detection: the case for early detection. Nature Rev. Cancer 3, 243-252 (2003). Important overview of the central role of early detection in the fight against cancer.
2. Boyes DA. The value of a Pap smear program and suggestions for its implementation. Cancer 48, 613-621 (1981).
3. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659-1665 (2001).
4. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646-650 (1977). One of thr first papers describing free DNA from solid tumors in the bloodstream of cancer patients.
5. Sozzi G, Conte D, Mariani L et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61, 4675-4678 (2001).
6. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 21, 5462-5482 (2002). Overview of DNA methylation changes in the most common cancer in women in the western world.
7. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet. 21, 163-167 (1999).
8. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21 (2002). Excellent review of mammalian DNA methylation.
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415-428 (2002). Very important overview of the fundamental role of epigenetic changes during tumorigenesis.
10. Laird PW. Early detection: the power and the promise of DNA methylation markers. Nature Rev. Cancer 3, 253-266 (2003). Review of the possible power of DNA methylation markers in early detection.
11. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89, 1827-1831 (1992).
12. Rein T, DePamphilis ML, Zorbas H. Identifying 5-methylcytosine and related modifications in DNA genomes. Nucleic Acids Res. 26, 2255-2264 (1998).
13. Gonzalgo ML, Bender CM, You EH et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 57, 5336-5347 (1997).
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad Sci. USA 93, 9821-9826 (1996). First paper describing methylation-specific PCR.
15. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25, 2529-2531 (1997).
16. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532-2534 (1997).
17. Gonzalgo ML, Liang G, Spruck CH III, Zingg JM, Rideout WM III, Jones PA. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR Cancer Res. 57, 594-599 (1997).
18. Eads CA, Lord RV, Wickramasighe K et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61, 3410-3418 (2001).
19. Eads CA, Lord RV, Kurumboor SK et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 60, 5021-5026 (2000).
20. Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28, E32 (2000). Described the MethyLight technique for the first time.
21. Lo YMD, Wong IHN, Zhang J, Tein MSC, Ng MHL, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59, 3899-3903 (1999).
22. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
23. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60, 5941-5945 (2000).
24. Wong IH, Lo YM, Zhang J et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71-73 (1999).
25. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6, 3516-3521 (2000).
26. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92, 1805-1811 (2000).
27. Mulcahy HE, Lyautey J, Lederrey C et al. Plasma DNA k-ras mutations in patients with gastrointestinal malignancies. Ann. NY Acad. Sci. 906, 25-28 (2000).
28. Widschwendter M, Jones PA. The potential prognostic, predictive and therapeutic values of DNA methylation in cancer: commentary re: Kwong J et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137 (2002) and Zou H-Z et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188-191 (2002). Clin. Cancer Res. 8, 17-21 (2002).
29. Widschwendter M, Jones PA. The potential prognostic, predictive and therapeutic values of DNA methylation in cancer: commentary re: Kwong J et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137 (2002) and Zou H-Z et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188-191 (2002). Clin. Cancer Res. 8, 17-21 (2002).
30. Widschwendter M, Jones PA. The potential prognostic, predictive and therapeutic values of DNA methylation in cancer: commentary re: Kwong J et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137 (2002) and Zou H-Z et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188-191 (2002). Clin. Cancer Res. 8, 17-21 (2002).
31. Markl ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res. 61, 5875-5884 (2001).
32. Greger V, Debus N, Lohmann D, Hopping W, Passarge E, Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum. Genet. 94, 491-496 (1994).
33. Bachman KE, Herman JG, Corn PG et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain and other human cancers. Cancer Res. 59, 798-802 (1999).
34. Yin D, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 21, 8372-8378 (2002).
35. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A suppressor gene in medulloblastoma development. Cancer Res. 62, 5906-5911 (2002).
36. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res. 62, 3794-3797 (2002).
37. Zardo G, Tiirikainen MI, Hong C et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nature Genet. 32, 453-458 (2002).
38. Dong S, Pang JC, Hu J, Zhou LF, Ng HK. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int. J. Cancer 98, 370-375 (2002).
39. Wolter M, Reifenberger J, Blaschke B et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKV2A (MTS1, p16INK4a), p14ARF and CDKV2B (MTS2, p15INK4b) tumor suppressor genes. J. Neuropathol. Exp. Neurol. 60, 1170-1180 (2001).
40. Li Q, Jedlicka A, Ahuja N et al. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 16, 3197-3202 (1998).
41. Zhang SJ, Endo S, Ichikawa T, Washiyama K, Kumanishi T. Frequent deletion and 5′CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res. 58, 1231-1237 (1998).
42. Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18, 3284-3289 (1999).
43. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797 (1999).
44. Farrell WE, Simpson DJ, Frost SJ, Clayton RN. Methylation mechanisms in pituitary tumorigenesis. Endocr. Relat. Cancer 6, 437-447 (1999).
45. Simpson DJ, Clayton RN, Farrell WE. Preferential loss of death-associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21, 1217-1224 (2002).
46. Seemann N, Kuhn D, Wrocklage C et al. CDKV2A/p16 inactivation is related to pituitary adenoma type and size. J. Pathol. 193, 491-497 (2001).
47. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 60, 1211-1216 (2000).
48. Gonzalez-Gomez P, Bello MJ, Alonso ME et al. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br. J. Cancer 88, 109-114 (2003).
49. Rhodes CH, Honsinger C, Sorenson GD. Detection of tumor-derived DNA in cerebrospinal fluid. J. Neuropathol. Exp. Neurol. 53(4), 364-368 (1994).
50. Swinkels DW, de Kok JB, Hanselaar A, Lamers K, Boerman RH. Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin. Chem. 46(1), 132-133 (2000).
51. Weinberg A, Li S, Palmer M, Tyler KL. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Ann. Neurol. 52, 543-548 (2002).
52. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
53. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21, 4231-4236 (2002).
54. Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP. Detection of hypermethylated RIZ1 gene in primary tumor, mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient. Clin. Cancer Res. 9, 1033-1038 (2003).
55. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21, 5450-5461 (2002). Excellent overview of DNA changes in lung cancer.
56. Tokugawa T, Sugihara H, Tani T, Hattori T. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res. 62, 4938-4944 (2002).
57. Corn PG, Heath EI, Heitmiller R et al. Frequent hypermethylation of the 5′CpG island of E-cadherin in esophageal adenocarcinoma. Clin. Cancer Res. 7, 2765-2769 (2001).
58. Shimada Y, Sato F, Watanabe G et al. Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma but not with the patient's prognosis and smoking history. Cancer 89(1), 5-11 (2000).
59. Xing EP, Nie Y, Song Y et al. Mechanisms of inactivation of p14ARF, p15INK4b and p16INK4a genes in human esophageal squamous cell carcinoma. Clin. Cancer Res. 5, 2704-2713 (1999).
60. Barrett MT, Sanchez CA, Prevo LJ et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nature Genet. 22, 106-109 (1999).
61. Wong DJ, Paulson TG, Prevo LJ et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 61, 8284-8289 (2001).
62. Hibi K, Taguchi M, Nakayama H et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 7, 3135-3138 (2001).
63. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. Inactivation of CACNA1 G, a T-type calcium channel gene, by aberrant methylation of its 5′CpG island in human tumors. Cancer Res. 59, 4535-4541 (1999).
64. Carvalho R, Kayademir T, Soares P et al. Loss of heterozygosity and promoter methylation but not mutation may underlie loss of TFF1 in gastric carcinoma. Lab. Invest. 82(10), 1319-1326 (2002).
65. Oue N, Motoshita J, Yokozaki H et al. Distinct promoter hypermethylation of p16INK4a, CDH1 and RAR-β in intestinal, diffuse-adherent and diffuse-scattered type gastric carcinomas. J. Pathol. 198, 55-59 (2002).
66. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. 82(3), 285-291 (2002).
67. Fleisher AS, Esteller M, Tamura G et al. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20, 329-335 (2001).
68. Kikuchi T, Itoh F, Toyota M et al. Aberrant methylation and histone deacetylation of cyclooxygenase-2 in gastric cancer. Int. J. Cancer 97, 272-277 (2002).
69. Nakajima T, Akiyama Y, Shiraishi J et al. Age-related hypermethylation of the hMLH1 promoter in gastric cancers. Int. J. Cancer 94, 208-211 (2001).
70. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 61, 7034-7038 (2001).
71. Oue N, Shigeishi H, Kuniyasu H et al. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int. J. Cancer 93, 805-809 (2001).
72. Jang TJ, Kim DI, Shin YM, Chang HK, Yang CH. p16(INK4a) promoter hypermethylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int. J. Cancer 93, 629-634 (2001).
73. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61, 2847-2851 (2001).
74. Machado JC, Oliveira C, Carvalho R et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20, 1525-1528 (2001).
75. Tamura G, Yin J, Wang S et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J. Natl. Cancer Inst. 92(7), 569-573 (2000).
76. To KF, Leung WK, Lee TL et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int. J. Cancer 102, 623-628 (2002).
77. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T. Promoter methylation status of E-cadherin, hMLH1 and p16 genes in non-neoplastic gastric epithelia. Am. J. Pathol. 161 (2), 399-403 (2002).
78. Lee TL, Leung WK, Chan MW et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res. 8, 1761-1766 (2002).
79. Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer. J. Pathol. 195, 111-134 (2001). Excellent review on DNA methylation changes in colorectal cancer.
80. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61, 3573-3577 (2001).
81. Sato F, Shibata D, Harpaz N et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 62, 6820-6822 (2002).
82. Sato F, Harpaz N, Shibata D et al. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 62, 1148-1151 (2002).
83. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst. 93(17), 1307-1313 (2001).
84. Nakagawa H, Nuovo GJ, Zervos EE et al. Age-related hypermethylation of the 5′region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 61, 6991-6995 (2001).
85. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51, 2116-2120 (1983).
86. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61, 900-902 (2001).
87. Nakayama H, Hibi K, Taguchi M et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 188, 115-119 (2002).
88. Zou HZ, Yu BM, Wang ZW et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188-191 (2002).
89. Lecomte T, Berger A, Zinzindohoue F et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100, 542-548 (2002).
90. Cui H, Cruz-Correa M, Giardiello FM et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753-1755 (2003).
91. Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N. Engl. J. Med. 346, 311-320 (2002).
92. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229 (2001).
93. Miyamoto K, Asada K, Fukutomi T et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22, 274-280 (2003).
94. Ueki T, Toyota M, Skinner H et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 61, 8540-8546 (2001).
95. Rosty C, Ueki T, Argani P et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160(1), 45-50 (2002).
96. Fukushima N, Sato N, Ueki T et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol. 160(5), 1573-1581 (2002).
97. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22, 924-934 (2003).
98. Kikuchi T, Toyota M, Itoh F et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 21, 2741-2749 (2002).
99. Matsumura T, Makino R, Mitamura K. Frequent downregulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin. Cancer Res. 7, 594-599 (2001).
100. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 61, 8094-8099 (2001).
101. Zhang YJ, Chen Y, Ahsan H et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int. J. Cancer 103, 440-444 (2003).
102. Yu J, Ni M, Xu J et al. Methylation profiling of twenty promoter CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2, 29 (2002).
103. Zhang YJ, Ahsan H, Chen Y et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 35, 85-92 (2002).
104. Nagai H, Kim YS, Konishi N et al. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett. 186, 59-65 (2002).
105. Matsukura S, Soejima H, Nakagawachi T et al. CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br. J. Cancer 88(4), 521-529 (2003).
106. Wong IH, Lo YM, Lai PB, Johnson PJ. Relationship of p16 methylation status and serum α-fetoprotein concentration in hepatocellular carcinoma patients. Clin. Chem. 46(9), 1420-1422 (2000).
107. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9, 1047-1052 (2003).
108. Goessl C, Muller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur. Urol. 41, 668-676 (2002).
109. Cheng P, Schmutte C, Cofer KF, Felix JC, Yu MC, Dubeau L. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer 75(3), 396-402 (1997).
110. Strathdee G, Mackean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341 (1999).
111. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92(7), 564-569 (2000).
112. Strathdee G, Appleton K, Illand M et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 158(3), 1121-1127 (2001).
113. Gras E, Catasus L, Arguelles R et al. Microsatellite instability, MLH-1 promoter hypermethylation and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92(11), 2829-2836 (2001).
114. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217 (2001).
115. Wong YF, Chung TK, Cheung TH et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 136, 231-235 (1999).
116. Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer 79, 61-65 (1998).
117. Shridhar V, Bible KC, Staub J et al. Loss of expression of a new member of the DNA J protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 61, 4258-4265 (2001).
118. McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol. Oncol. 72, 87-92 (1999).
119. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. Satellite DNA hypomethylation versus overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat. Res. 423(1-2), 91-101 (1999).
120. Ahluwalia A, Yan P, Hurteau JA et al. DNA methylation and ovarian cancer. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol. 82, 261-268 (2001).
121. Wei SH, Chen CM, Strathdee G et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8, 2246-2252 (2002).
122. Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA. Molecular detection of tumour DNA in serum and penitoneal fluid from ovarian cancer patients. Br. J. Cancer 80(11), 1803-1808 (1999).
123. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17, 2413-2417 (1998).
124. Simpkins SB, Bocker T, Swisher EM et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 8(4), 661-666 (1999).
125. Esteller M, Catasus L, Matias-Guiu X et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155(5), 1767-1772 (1999).
126. Sasaki M, Oh BR, Dharia A, Fujimoto S, Dahiya R. Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer. Mol. Carcinog. 29(2), 59-66 (2000).
127. Salvesen HB, MacDonald N, Ryan A et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22-26 (2001).
128. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 61, 97-102 (2001).
129. Zysman M, Saka A, Millar A, Knight J, Chapman W, Bapat B. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res. 62, 3663-3666 (2002).
130. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 94(11), 2941-2952 (2002).
131. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res. 61, 3262-3266 (2001).
132. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res. 59, 462-466 (1999).
133. Salvesen HB, MacDonald N, Ryan A et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin. Cancer Res. 6, 3607-3613 (2000).
134. Horowitz N, Pinto K, Mutch DG et al. Microsatellite instability, MLH1 promoter methylation and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol. Oncol. 86, 62-68 (2002).
135. Whelan AJ, Babb S, Mutch DG et al. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int. J. Cancer 99, 697-704 (2002).
136. Martini M, Ciccarone M, Garganese G et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int. J. Cancer 102, 398-406 (2002).
137. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7, 1982-1986 (2001).
138. Ivanova T, Petrenko A, Gritsko T et al. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer 2, 4 (2002).
139. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7, 584-589 (2001).
140. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N. Engl. J. Med. 345, 555-560 (2001).
141. Sullivan PM, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93(14), 1054-1061 (2001). Introduction of five phases of biomarker development.
142. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genet. 32(3), 355-357 (2002).